Currently Viewing:
Newsroom
Currently Reading
Polypharmacy Plays a Role in Patients With Relapsing-Remitting Multiple Sclerosis
February 17, 2019 – Laura Joszt
Review Find Moderate Evidence That Aerobic Exercise Lowers Number of Migraine Days
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019

AJMC® in the Press, December 7, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The Washington Examiner’s article on privatizing public funds for healthcare included a study published in The American Journal of Managed Care®. The study, “Medicaid Managed Care Reduces Readmissions for Youths With Type 1 Diabetes,” found that youths with type 1 diabetes on Medicaid managed care were less likely to be readmitted within 90 days of discharge, adjusting for severity, despite rates of diabetic ketoacidosis.

A study published in AJMC® was mentioned in articles from Skilled Nursing News and McKnight’s Long-Term Care News. The study, “Medicare Advantage Control of Postacute Costs: Perspectives From Stakeholders,” examined the methods that Medicare Advantage (MA) plans use to control or reduce postacute spending and their associated unintended consequences. The researchers found that in their interactions with hospitals and skilled nursing facilities (SNFs), MA plans attempted to influence the choice of SNF and length of stay to control postacute spending. However, exerting too much influence over hospitals and SNFs may have the negative consequences of delayed hospital discharge and SNFs’ avoidance of burdensome plans.

The University of Michigan Center for Value-Based Insurance Design’s Center Policy Update mentioned the AJMC® study “Understanding and Improving Value Frameworks With Real-World Patient Outcomes.” The study concluded that collective stakeholders that include key decision makers within our healthcare system need to recognize the importance of implementing real-world evidence and devote resources to further research into the chronic disease areas in which the impact of human behavior is amplified by the duration of disease and treatment.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed highlighted an article from AJMC®’s 60th American Society of Hematology Annual Meeting and Exposition coverage. The article, “Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings,” reported on a multicenter retrospective study that evaluated the efficacy and safety of the chimeric antigen receptor (CAR) T-cell treatment in a real-world setting and found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.

Tuesday’s CER Daily Newsfeed included an AJMC® interview with Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc. During the interview, Kolodziej explained that while new therapies like CAR T-cell therapy can have amazing results, the innovation of these treatments has outstripped the United States’ ability to pay for them.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!